These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 566875)

  • 1. The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper.
    Weiner WJ; Nausieda PA; Klawans HL
    Neurology; 1978 Jul; 28(7):734-7. PubMed ID: 566875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
    Silbergeld EK; Pfeiffer RF
    J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of L-dopa and lergotrile mesylate on the interaction of fluphenazine decanoate and amphetamine-induced stereotypy and mortality.
    Lemberger L; Kellams JJ; Small JG; Rowe H
    Commun Psychopharmacol; 1977; 1(5):501-7. PubMed ID: 564259
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
    Teychenne PF; Rosin AJ; Plotkin CN; Calne DB
    Br J Clin Pharmacol; 1980 Jan; 9(1):47-50. PubMed ID: 6101955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxial response to dopaminergic agents in parkinsonism.
    Wiener WJ; Kramer J; Nausieda PA; Klawans HL
    Arch Neurol; 1978 Jul; 35(7):453-5. PubMed ID: 666596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G; Moore KE
    Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trace metals and biogenic amines in rat brain.
    Donaldson J; Cloutier T; Minnich JL; Barbeau A
    Adv Neurol; 1974; 5():245-52. PubMed ID: 4440574
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice.
    Sinha YN; Salocks CB; VanderLaan WP
    Horm Metab Res; 1976 Sep; 8(5):332-6. PubMed ID: 989755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of reflex effects of levodopa and bromocriptine in Parkinsonism.
    McLellan DL
    Br Med J; 1976 Jul; 2(6029):235-6. PubMed ID: 989742
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of chronic bromocriptine and levodopa administration on cerebral type 1 cannabinoid receptor binding.
    Casteels C; Vanbilloen B; Vercammen D; Bosier B; Lambert DM; Bormans G; Van Laere K
    Synapse; 2010 Aug; 64(8):617-23. PubMed ID: 20340169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of bromocriptine and lergotrile in renal and spontaneously hypertensive rats.
    Tadepalli AS; Novak PJ
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):93-105. PubMed ID: 6141774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of haloperidol pre- and post-treatment on the ability of pergolide and bromocriptine to antagonize the gamma-butyrolactone-induced increase in brain dopamine in rats.
    Fuller RW; Perry KW
    Biochem Pharmacol; 1982 Jun; 31(12):2199-200. PubMed ID: 7115441
    [No Abstract]   [Full Text] [Related]  

  • 18. Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine.
    Keller HH; Da Prada M
    Life Sci; 1979 Mar; 24(13):1211-21. PubMed ID: 36540
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of bromocriptine on dopamine turnover with or without levodopa.
    Ogawa N; Asanuma M; Tanaka K; Matsuura K; Iida K; Yamamoto M
    J Int Med Res; 1996; 24(3):271-7. PubMed ID: 8725988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective affinities of bromocriptine and lergotrile for rat limbic dopamine binding sites [proceedings].
    Blackburn KJ; Bremner RM; Greengrass PM; Morville M; Davey MJ
    Br J Pharmacol; 1978 Nov; 64(3):413P. PubMed ID: 31219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.